Why The FDA Probably Won't Approve An Expanded Indication For Amarin's …

Why The FDA Probably Won't Approve An Expanded Indication For Amarin's …

On Wednesday an FDA advisory panel will consider an expanded indication for Amarin Pharmaceuticals' Vascepa, an EPA fish oil product currently indicated only for people with severe hypertriglyceridemia (>500 mg/dl). The new indication would greatly 

10
Like
Save

Comments

Write a comment

*